Key result
A 30-mg intravenous bolus of APSAC induced coronary artery reperfusion in 60% of patients with acute transmural myocardial infarction, compared to 21% with a 5-mg dose.
Why the study?
Does anisoylated plasminogen: streptokinase activator complex (APSAC) induce coronary artery reperfusion in patients with acute transmural myocardial infarction and complete coronary artery occlusion?
Population
29 patients with acute transmural myocardial infarction and complete coronary artery occlusion
Design
Case_series
Follow-up
24 hours
Authors
Loading...
Supports APSAC dose exploration in acute MI; hypothesis-generating from Level 5 data and requires randomized confirmation before practice change.
Does anisoylated plasminogen: streptokinase activator complex (APSAC) induce coronary artery reperfusion in patients with acute transmural myocardial infarction and complete coronary artery occlusion?
Absolute Event Rate: 60% vs 21%
A 30-mg intravenous bolus of APSAC rapidly induces coronary reperfusion in a majority of patients with acute transmural myocardial infarction, suggesting its utility as an early fibrinolytic treatment.
Victor J. Marder (1986) studied Acute transmural myocardial infarction and complete coronary artery occlusion (n=29). Anisoylated plasminogen: streptokinase activator complex (APSAC) vs. 5-mg dose was evaluated on Coronary artery reperfusion. A 30-mg intravenous bolus of APSAC induced coronary artery reperfusion in 60% of patients with acute transmural myocardial infarction, compared to 21% with a 5-mg dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: